• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

36.35 +0.01 (+0.03%)
Delayed Quote Updated: 11:12 AM EDT, Oct 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 93,221
Open 36.35
Bid (Size) 36.35 (700)
Ask (Size) 36.36 (700)
Prev. Close 36.34
Today's Range 36.35 - 36.39
52wk Range 18.80 - 36.66
Shares Outstanding 44,454,792
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
October 12, 2026
From Kahn Swick & Foti, LLC
Via Business Wire
Top stock movements in today's session. ↗
October 08, 2026
Via Chartmill

Performance

52-Week Range 0.9% below 52-week high
36.35
18.8052W Low 36.6652W High
1 Week 0.9% below 1-week high
36.301W Low 36.661W High

Pacira BioSciences, Inc. - Common Stock (PCRX) traded between $18.80 and $36.66 over the past 52 weeks and last traded at $36.35, 0.9% below its 52-week high. Over the past week it ranged between $36.30 and $36.66.

Past 12 Months
N/A
+47.2%
+43.4%
+46.0%
+48.6%
+57.9%
1W  
1M +$11.66
3M +$11.00
6M +$11.45
YTD +$11.89
1Y +$13.33

PCRX was +57.9% over the past year, +46.0% over six months, +48.6% year to date.

12 Months vs Market
PCRX
+57.9%
DIA
+11.3%
SPY
+14.5%
QQQ
+18.1%
IWM
+9.6%

Over the past 12 months PCRX returned +57.9% versus DIA (Dow) +11.3%, SPY (S&P 500) +14.5%, QQQ (Nasdaq 100) +18.1% and IWM (Russell 2000) +9.6%.

Volume & Liquidity 0.08× 3-mo avg
Today 93,221 3-mo avg 1.2M
1W
1.9M
1M
2.4M
3M
1.2M
6M
873.7K
YTD
860.3K
1Y
843.6K

PCRX most recently traded 93,221 shares against a 3-month average daily volume of 1.2M.

More News

Read More
Let's take a look at the stocks that are in motion in today's session. ↗
October 08, 2026
Via Chartmill
News headline image
Why Pacira BioSciences Skyrocketed Today ↗
October 08, 2026
Via The Motley Fool
Pacira Biosciences (NASDAQ:PCRX): An Undervalued Value Stock Backed by Cash Flow and Balance Sheet Strength ↗
September 11, 2026
Via Chartmill
Pacira Biosciences (NASDAQ:PCRX): A Value Play with Fundamentals Intact ↗
August 17, 2026
Via Chartmill
Traders are paying attention to the gapping stocks in Thursday's session. ↗
October 08, 2026
Via Chartmill
News headline image
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
October 08, 2026
From Halper Sadeh LLC
Via Business Wire
News headline image
Pacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home
October 07, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom
October 05, 2026
From Pacira BioSciences
Via GlobeNewswire
Pacira Biosciences (NASDAQ:PCRX) Beats Q2 EPS Estimates, Misses on Revenue and Cuts Outlook ↗
August 04, 2026
Via Chartmill
Pacira Biosciences Inc (NASDAQ:PCRX) Emerges as a Deep Value Opportunity with Strong Financial Health ↗
June 02, 2026
Via Chartmill
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 09, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira (PCRX) Q2 2026 Earnings Call Transcript ↗
August 12, 2026
Via The Motley Fool
Topics Earnings
News headline image
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
August 06, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Q2 Earnings Call Highlights ↗
August 04, 2026
Via MarketBeat
Topics Earnings
News headline image
Pacira BioSciences Reports Second Quarter 2026 Financial Results
August 04, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce
July 28, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
July 27, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
July 22, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 08, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
July 01, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
June 30, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees
May 28, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees
May 27, 2026
From Pacira BioSciences
Via GlobeNewswire

Frequently Asked Questions

Is Pacira BioSciences, Inc. - Common Stock publicly traded?
Yes, Pacira BioSciences, Inc. - Common Stock is publicly traded.
What exchange does Pacira BioSciences, Inc. - Common Stock trade on?
Pacira BioSciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Pacira BioSciences, Inc. - Common Stock?
The ticker symbol for Pacira BioSciences, Inc. - Common Stock is PCRX on the Nasdaq Stock Market
What is the current price of Pacira BioSciences, Inc. - Common Stock?
The current price of Pacira BioSciences, Inc. - Common Stock is 36.35
When was Pacira BioSciences, Inc. - Common Stock last traded?
The last trade of Pacira BioSciences, Inc. - Common Stock was at 10/19/26 11:12 AM ET
What is the market capitalization of Pacira BioSciences, Inc. - Common Stock?
The market capitalization of Pacira BioSciences, Inc. - Common Stock is 1.62B
How many shares of Pacira BioSciences, Inc. - Common Stock are outstanding?
Pacira BioSciences, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap